Sorafenib tosylate-loaded nanosuspension: preparation, optimization, and in vitro cytotoxicity study against human HepG2 carcinoma cells

References

• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3.
   PubMed Web of Science ®Google Scholar
• Oluyomi AO, El-Serag HB, Olayode A, et al. Neighborhood-level factors contribute to disparities in hepatocellular carcinoma incidence in Texas. Clin Gastroenterol Hepatol. 2023;21(5):1314–1322.e5. doi:10.1016/j.cgh.2022.06.031.
   PubMed Web of Science ®Google Scholar
• Apisarnthanarax S, Barry A, Cao M, et al. External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2022;12(1):28–51. doi:10.1016/j.prro.2021.09.004.
   PubMed Web of Science ®Google Scholar
• Podlasek A, Abdulla M, Broering D, et al. Recent advances in locoregional therapy of hepatocellular carcinoma. Cancers (Basel). 2023;15(13):3347. doi:10.3390/cancers15133347.
   PubMed Web of Science ®Google Scholar
• Yin Z, Chen D, Liang S, et al. Neoadjuvant therapy for hepatocellular carcinoma. J Hepatocell Carcinoma. 2022;9:929–946. doi:10.2147/JHC.S357313.
   PubMed Web of Science ®Google Scholar
• Ruman U, Buskaran K, Pastorin G, et al. Synthesis and characterization of chitosan-based nanodelivery systems to enhance the anticancer effect of sorafenib drug in hepatocellular carcinoma and colorectal adenocarcinoma cells. Nanomaterials. 2021;11(2):497. doi:10.3390/nano11020497.
   Web of Science ®Google Scholar
• Li Z, Ye L, Liu J, et al. Sorafenib-loaded nanoparticles based on biodegradable dendritic polymers for enhanced therapy of hepatocellular carcinoma. Int J Nanomedicine. 2020;15:1469–1480. doi:10.2147/IJN.S237335.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307. doi:10.1038/nature10144.
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumour microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31(17):2205–2218. doi:10.1200/JCO.2012.46.3653.
   PubMed Web of Science ®Google Scholar
• Awasthi R, Roseblade A, Hansbro PM, et al. Nanoparticles in cancer treatment: opportunities and obstacles. Curr Drug Targets. 2018;19(14):1696–1709. doi:10.2174/1389450119666180326122831.
   PubMed Web of Science ®Google Scholar
• Sarkar M, Wang Y, Ekpenyong O, et al. Pharmacokinetic behaviors of soft nanoparticulate formulations of chemotherapeutics. Nanomed Nanobiotechnol. 2023;15(2):e1846.
   Web of Science ®Google Scholar
• Rasool M, Malik A, Waquar S, et al. New challenges in the use of nanomedicine in cancer therapy. Bioengineered. 2022;13(1):759–773. doi:10.1080/21655979.2021.2012907.
   PubMed Web of Science ®Google Scholar
• Ma Y, Cong Z, Gao P, et al. Nanosuspensions technology as a master key for nature products drug delivery and in vivo fate. Eur J Pharm Sci. 2023;185:106425. doi:10.1016/j.ejps.2023.106425.
   PubMed Web of Science ®Google Scholar
• Ferrar JA, Sellers BD, Chan C, et al. Towards an improved understanding of drug excipient interactions to enable rapid optimization of nanosuspension formulations. Int J Pharm. 2020;578:119094. doi:10.1016/j.ijpharm.2020.119094.
   PubMed Web of Science ®Google Scholar
• Saraswat AL, Vartak R, Hegazy R, et al. Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs). Drug Discov Today. 2023;28(1):103387. doi:10.1016/j.drudis.2022.103387.
   PubMed Web of Science ®Google Scholar
• Jacob S, Nair AB, Sha J. Emerging role of nanosuspensions in drug delivery systems. Biomat Res. 2020;24:3.
   PubMedGoogle Scholar
• Sampathi S, Haribhau CJ, Kuchana V, et al. Nanosuspension encapsulated chitosan-pectin microbeads as a novel delivery platform for enhancing oral bioavailability. Carbohydr Polym. 2023;319:121177. doi:10.1016/j.carbpol.2023.121177.
   PubMed Web of Science ®Google Scholar
• Sher M, Zahoor M, Shah SWA, et al. Is particle size reduction linked to drug efficacy: an overview into nano initiatives in pharmaceuticals. Zeitschrift Physikalische Chem. 2023;237(7):845–877. doi:10.1515/zpch-2023-0221.
   Web of Science ®Google Scholar
• Pezik E, Gulsun T, Gunduz MG, et al. Preparation of nanosuspensions of a 1,4-dihydropyridine-based mixed L-/T-type calcium channel blocker by combined precipitation and ultrasonication methods. J Drug Deliv Sci Technol. 2023;87:104772. doi:10.1016/j.jddst.2023.104772.
   Web of Science ®Google Scholar
• Lee SH, Kim JK, Jee JP, et al. Quality by design (QbD) application for the pharmaceutical development process. J Pharm Investig. 2022;52(6):649–682. doi:10.1007/s40005-022-00575-x.
   Web of Science ®Google Scholar
• Rampado R, Peer D. Design of experiments in the optimization of nanoparticle-based drug delivery systems. J Control Release. 2023;358:398–419. doi:10.1016/j.jconrel.2023.05.001.
   PubMed Web of Science ®Google Scholar
• Cooper RG, Edgett SJ, Kleinschmidt EJ. Optimizing the stage-gate process: what best-practice companies do-I. Res Technol Manag. 2002;45(5):21–27. doi:10.1080/08956308.2002.11671518.
   Web of Science ®Google Scholar
• Anandam S, Selvamuthukumar S. Optimization of microwave-assisted synthesis of cyclodextrin nanosponges using response surface methodology. J Porous Mater. 2014;21(6):1015–1023. doi:10.1007/s10934-014-9851-2.
   Web of Science ®Google Scholar
• Beg S, Swain S, Rahman M, et al. Application of design of experiment (DoE) in pharmaceutical product and process optimization, in pharmaceutical quality by design. In: Beg S, Hasnain MS, editors. Pharmaceutical quality by design. United States, MA: Cambridge, 2019;43–64.
   Google Scholar
• Bhattacharya S. Central composite design for response surface methodology and its application in pharmacy. In: Response surface methodology in engineering. London, United Kingdom: Intech. Open. 2021;1–21
   Google Scholar
• Djoudi W, Aissani-Benissad F, Bourouina-Bacha S. Optimization of copper cementation process by iron using Central composite design experiments. Chem Eng J. 2007;133(1-3):1–6. doi:10.1016/j.cej.2007.01.033.
   Web of Science ®Google Scholar
• Acıkalın K, Karaca F, Bolat E. Central composite rotatable design for liquefaction of pine barks. Fuel Process Technol. 2005;87(1):17–24. doi:10.1016/j.fuproc.2005.04.005.
   Web of Science ®Google Scholar
• Rakic T, Kasagic-Vujanovic I, Jovanovic M, et al. Comparison of full factorial design, Central composite design, and box-behnken design in chromatographic method development for the determination of fluconazole and its impurities. Anal Lett. 2014;47(8):1334–1347.
   Web of Science ®Google Scholar
• Peter S, Mathews MM, Saju F, et al. Development, optimization and in vitro characterization of eudragit-ganciclovir nanosuspension or treating herpes simplex keratitis. J Pharm Innov. 2023. doi:10.1007/s12247-023-09723-8.
   Web of Science ®Google Scholar
• Waghule T, Saha RN, Alexander A, et al. Tailoring the multi-functional properties of phospholipids for simple to complex self-assemblies. J Control Release. 2022;349:460–474. doi:10.1016/j.jconrel.2022.07.014.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Chen H, Zeng X, et al. Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system of TRAIL and endostatin for cervical cancer gene therapy. Nanoscale Res Lett. 2013;8(1):161. doi:10.1186/1556-276X-8-161.
   PubMedGoogle Scholar
• Yan H, Du X, Wang R, et al. Progress in the study of D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) reversing multidrug resistance. Colloids Surf B Biointerfaces. 2021;205:111914. doi:10.1016/j.colsurfb.2021.111914.
   PubMed Web of Science ®Google Scholar
• Yang S, Zhang B, Gong X, et al. In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer. Int J Nanomedicine. 2016;11:2329–2343. doi:10.2147/IJN.S104119.
   PubMed Web of Science ®Google Scholar
• Matteucci ME, Hotze MA, Johnston KP, et al. Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir. 2006;22(21):8951–8959. doi:10.1021/la061122t.
   PubMed Web of Science ®Google Scholar
• Singh MK, Pooja D, Ravuri HG, et al. Fabrication of surfactant-stabilized nanosuspension of naringenin to surpass its poor physiochemical properties and low oral bioavailability. Phytomedicine. 2018;40:48–54. doi:10.1016/j.phymed.2017.12.021.
   PubMed Web of Science ®Google Scholar
• Shaikh F, Patel M, Patel V, et al. Formulation and optimization of cilnidipine loaded nanosuspension for the enhancement of solubility, dissolution and bioavailability. J Drug Deliv Sci Technol. 2022;69:103066. doi:10.1016/j.jddst.2021.103066.
   Web of Science ®Google Scholar
• Liu Y, Feng L, Liu T, et al. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer. Nanoscale. 2014;6(6):3231–3242. doi:10.1039/c3nr05647c.
   PubMed Web of Science ®Google Scholar
• Mishra B, Arya N, Tiwari S. Investigation of formulation variables affecting the properties of lamotrigine nanosuspension using fractional factorial design. DARU J Pharm Sci. 2010;18(1):1–8.
   Web of Science ®Google Scholar
• Bose S, Sharma P, Mishra V, et al. Comparative in vitro evaluation of glimepiride containing nanosuspension drug delivery system developed by different techniques. J Mol Struct. 2021;1231:129927. doi:10.1016/j.molstruc.2021.129927.
   Web of Science ®Google Scholar
• Singh AK, Singh SS, Rathore AS, et al. Lipid-coated MCM-41 mesoporous silica nanoparticles loaded with berberine improved inhibition of acetylcholine esterase and amyloid formation. ACS Biomater Sci Eng. 2021;7(8):3737–3753. doi:10.1021/acsbiomaterials.1c00514.
   PubMed Web of Science ®Google Scholar
• Khatak S, Mehta M, Awasthi R, et al. Solid lipid nanoparticles containing anti-tubercular drugs attenuate the Mycobacterium marinum infection. Tuberculosis (Edinb). 2020;125:102008. doi:10.1016/j.tube.2020.102008.
   PubMed Web of Science ®Google Scholar
• Banarase NB, Kaur CD. Whole whey stabilized oleanolic acid nanosuspension: formulation and evaluation study. J Drug Deliv Sci Technol. 2022;67:103001. doi:10.1016/j.jddst.2021.103001.
   Web of Science ®Google Scholar
• Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988;48(3):589–601.
   PubMed Web of Science ®Google Scholar
• Noor F, Niklas J, Müller-Vieira U, et al. An integrated approach to improved toxicity prediction for the safety assessment during preclinical drug development using hep G2 cells. Toxicol Appl Pharmacol. 2009;237(2):221–231. doi:10.1016/j.taap.2009.03.011.
   PubMed Web of Science ®Google Scholar
• Singare DS, Marella S, Gowthamrajan K, et al. Optimization of formulation and process variable of nanosuspension: an industrial perspective. Int J Pharm. 2010;402(1–2):213–220. doi:10.1016/j.ijpharm.2010.09.041.
   PubMed Web of Science ®Google Scholar
• Shamma RN, Basalious EB, Shoukri R. Development of novel sustained release matrix pellets of betahistine dihydrochloride: effect of lipophilic surfactants and co-surfactants. Pharm Dev Technol. 2012;17(5):583–593. doi:10.3109/10837450.2011.557730.
   PubMed Web of Science ®Google Scholar
• Godara S, Lather V, Kirthanashri SV, et al. Lipid-PLGA hybrid nanoparticles of paclitaxel: preparation, characterization, in vitro and in vivo evaluation. Mater Sci Eng C Mater Biol Appl. 2020;109:110576. doi:10.1016/j.msec.2019.110576.
   PubMed Web of Science ®Google Scholar
• Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Control Release. 2004;100(1):5–28. doi:10.1016/j.jconrel.2004.08.010.
   PubMed Web of Science ®Google Scholar
• Elsayed MM, Mostafa ME, Alaaeldin E, et al. Design and characterisation of novel sorafenib-loaded carbon nanotubes with distinct tumour-suppressive activity in hepatocellular carcinoma. Int J Nanomedicine. 2019;14:8445–8467. doi:10.2147/IJN.S223920.
   PubMed Web of Science ®Google Scholar
• Wang X, Luo Z, Xiao Z. Preparation, characterization, and thermal stability of β-cyclodextrin/soybean lecithin inclusion complex. Carbohydr Polym. 2014;101:1027–1032. doi:10.1016/j.carbpol.2013.10.042.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz AG, Ganem A, Olivares-Corichi IM, et al. Lecithin-chitosan-TPGS nanoparticles as nanocarriers of (−)-epicatechin enhanced its anticancer activity in breast cancer cells. RSC Adv. 2018;8(61):34773–34782. doi:10.1039/c8ra06327c.
   PubMed Web of Science ®Google Scholar
• Marquele-Oliveira F, Torres EC, da Silva Barud H, et al. Physicochemical characterization by AFM, FT-IR and DSC and biological assays of a promising antileishmania delivery system loaded with a natural Brazilian product. J Pharm Biomed Anal. 2016;123:195–204. doi:10.1016/j.jpba.2016.01.045.
   PubMed Web of Science ®Google Scholar
• Yang L, Wu P, Xu J, et al. Development of apremilast solid dispersion using TPGS and PVPVA with enhanced solubility and bioavailability. AAPS PharmSciTech. 2021;22(4):142. doi:10.1208/s12249-021-02005-x.
   PubMed Web of Science ®Google Scholar
• Zhang T, Li X, Xu J, et al. Preparation, characterization, and evaluation of breviscapine nanosuspension and its freeze-dried powder. Pharmaceutics. 2022;14(5):923. doi:10.3390/pharmaceutics14050923.
   PubMed Web of Science ®Google Scholar
• Gao Y, Liao J, Qi X, et al. Coamorphous repaglinide-saccharin with enhanced dissolution. Int J Pharm. 2013;450(1–2):290–295. doi:10.1016/j.ijpharm.2013.04.032.
   PubMed Web of Science ®Google Scholar
• Abdelbary AA, Al-Mahallawi AM, Abdelrahim ME, et al. Preparation, optimization, and in vitro simulated inhalation delivery of carvedilol nanoparticles loaded on a coarse carrier intended for pulmonary administration. Int J Nanomedicine. 2015;10:6339–6353. doi:10.2147/IJN.S91631.
   PubMed Web of Science ®Google Scholar
• Benizri S, Ferey L, Alies B, et al. Nucleoside-lipid-based nanocarriers for sorafenib delivery. Nanoscale Res Lett. 2018;13(1):17. doi:10.1186/s11671-017-2420-2.
   PubMedGoogle Scholar
• Hong C, Dang Y, Lin G, et al. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation. Int J Pharm. 2014;477(1–2):251–260. doi:10.1016/j.ijpharm.2014.10.044.
   PubMed Web of Science ®Google Scholar
• Kalvakuntla S, Deshpande M, Attari Z, et al. Preparation and characterization of nanosuspension of aprepitant by H96 process. Adv Pharm Bull. 2016;6(1):83–90. doi:10.15171/apb.2016.013.
   PubMed Web of Science ®Google Scholar
• Nakarani M, Misra AK, Patel JK, et al. Itraconazole nanosuspension for oral delivery: formulation, characterization and in vitro comparison with marketed formulation. DARU. 2010;18(2):84.
   PubMed Web of Science ®Google Scholar
• Park JH, Baek MJ, Lee JY, et al. Preparation and characterization of sorafenib-loaded microprecipitated bulk powder for enhancing oral bioavailability. Int J Pharm. 2020;589:119836. doi:10.1016/j.ijpharm.2020.119836.
   PubMedGoogle Scholar
• Zhang S, Li J, Lykotrafitis G, et al. Size-dependent endocytosis of nanoparticles. Adv Mater. 2009;21(4):419–424. doi:10.1002/adma.200801393.
   PubMed Web of Science ®Google Scholar